Compare Dolby Laboratories, Inc. (DLB) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dolby Laboratories, Inc. vs Mesoblast Limited — how do they compare? Dolby Laboratories, Inc. trades at $58.9 (market cap $5.47B), while Mesoblast Limited trades at $13.8 (market cap $1.81B). The key difference: Dolby Laboratories, Inc. is far larger — about 3× Mesoblast Limited's market cap, and Dolby Laboratories, Inc. pays a 2.47% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dolby Laboratories, Inc. for 98 Days and Mesoblast Limited for 14 Days on average.
| DLB | MESO | |
|---|---|---|
Market Cap | $5.47B | $1.81B |
Volume | 691,016 | 240,620 |
Sector | Technology | Health |
52-Week High | $70.09 | $20.96 |
52-Week Low | $48.51 | $13.19 |
Typical Hold Time | 98 Days | 14 Days |
Enterprise Value | $4.84B | $1.89B |
Dividend Yield | 2.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dolby Laboratories (DLB) trades at $58.35, down 0.19% with bearish technical signals despite strong profitability margins. The company maintains robust fundamentals with 87.61% gross margins and consistent earnings beats, though revenue has plateaued around $1.3B. Recent leadership transition to Marc Whitten and expanded Meta partnership for Dolby Atmos/Vision represent key developments. Technical indicators show resistance at $59 with support at $58.
DLB offers stable cash flow generation and dividend income but faces growth challenges with flat revenue. Analyst consensus targets $90.33 (55% upside) with 47% buy ratings, though near-term execution risks and licensing volatility warrant caution. The stock presents value for income investors but requires revenue acceleration for significant appreciation.
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
